Vitamin D Supplementation for Treatment of Heart Failure

Phase 4

Terminated

Conditions: Heart Failure

Interventions: Drug: Placebo
Drug: Vitamin D3

Registration Number: NCT01230307

Lead Sponsor: University of Michigan

Brief Summary: The central objective of this proposal is to establish that vitamin D supplementation in heart failure patients with low vitamin D levels will have improved outcomes compared to placebo. In addition the investigators will also evaluate the role of genetics in regard to vitamin D and heart failure. The investigators will be evaluating what is currently a novel approach of identifying patients with low vitamin D and treating this low vitamin D level. The investigators will be able to evaluate the importance of vitamin D supplementation in these patients and the role of genetics on our defined outcomes.

Detailed Description: Primary Objective To determine how rapid vitamin D supplementation affects biomarkers and submaximal exercise capacity in systolic HF patients with low vitamin D status.

Working Hypothesis 1: HF patients when supplemented with vitamin D for 6 months will have lower measures of inflammation and extracellular-matrix remodeling compared with placebo.

Working Hypothesis 2: HF patients when supplemented with vitamin D for 6 months will have longer 6-minute walk length compared with placebo.

Secondary Objectives To establish a relationship between the CYP2R1 variant and surrogate markers in systolic HF patients.

Working Hypothesis 3: HF patients with the CYP2R1 G allele will have higher measures of inflammation and extracellular-matrix remodeling compared to AA subjects. This relationship will also be seen in subjects with the CYP2R1 TagSNP variants.

Working Hypothesis 4: HF patients with CYP2R1 variant alleles will have shorter 6-minute walk length compared to subjects without these variants.

To genotype HF subjects for the VDR variants and additional tag SNPs, to ascertain the relationship between VDR genetic variation and surrogate markers in systolic HF patients.

Working Hypothesis 5: HF patients with VDR variants will have greater measures of inflammation and extracellular-matrix remodeling compared to subjects without VDR variants.

Working Hypothesis 6: HF patients with VDR variants will have a shorter 6-minute walk length compared to subjects without these variants.

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 28

Inclusion Criteria

HF patients with LV systolic dysfunction of ischemic or non-ischemic origin and an LVEF <40% using nuclear ventriculography or echocardiography within the last 6 months.
Attempts should have been made at optimizing medical therapy and the participant should be stable on these medications for at least 3 months.
Patients with a 25(OH)D level between 10-25 ng/ml

Exclusion Criteria

Inability to give informed consent
Patients with sarcoidosis or other granulomatous disease that can alter vitamin D metabolism
Patients with primary valvular HF, hypertrophic cardiomyopathy, and drug-induced HF
Renal dysfunction defined as serum creatinine > 2.5 mg/dl
Pregnant women
Patients <18 years of age
Patients on vitamin D supplementation

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	A placebo loading dose will be given followed by two placebo tablets daily for 6 months.
Vitamin D	Vitamin D3	Vitamin D supplementation will be an oral load of 100,000 IU then 2000 IU by mouth daily of vitamin D3 (cholecalciferol)for 6 months

Primary Outcome Measures

Name	Time	Method
Biomarkers	6 months	Biomarkers - C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-a (TNF-a), propeptide procollagen type I, plasma procollagen III, matrix metalloproteinase 2 (MMP-2), MMP-9 and tissue inhibitor of matrix metalloproteinases-1 (TIMP-1).

Secondary Outcome Measures

Name	Time	Method
Exercise Capacity Measured by 6 Minute Walk Test	6 months
Quality of Life Measured by Kansas City Cardiomyopathy Questionnaire	6 months	Kansas City Cardiomyopathy Questionnaire for quality of life is measured on a scale of 0 - 100, with 100 being best.
Vitamin D Genomics	Baseline	Genotyped for the restricted fragment length polymorphism at the BsmI site. In addition CYP2R1, CYP27B1, CYP24 will also be genotyped.